Fjarde AP Fonden Fourth Swedish National Pension Fund Boosts Stock Position in Abbott Laboratories $ABT

Fjarde AP Fonden Fourth Swedish National Pension Fund grew its holdings in shares of Abbott Laboratories (NYSE:ABT) by 61.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 884,654 shares of the healthcare product maker’s stock after buying an additional 336,450 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Abbott Laboratories were worth $90,827,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. American National Bank of Texas boosted its stake in Abbott Laboratories by 2.4% during the 4th quarter. American National Bank of Texas now owns 3,408 shares of the healthcare product maker’s stock valued at $427,000 after acquiring an additional 79 shares during the last quarter. Nia Impact Advisors LLC raised its stake in shares of Abbott Laboratories by 2.2% in the 2nd quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock valued at $504,000 after purchasing an additional 79 shares in the last quarter. Park Place Capital Corp lifted its position in shares of Abbott Laboratories by 11.0% during the fourth quarter. Park Place Capital Corp now owns 815 shares of the healthcare product maker’s stock worth $102,000 after purchasing an additional 81 shares during the last quarter. Lantern Wealth Advisors LLC increased its holdings in Abbott Laboratories by 1.7% in the third quarter. Lantern Wealth Advisors LLC now owns 5,028 shares of the healthcare product maker’s stock valued at $674,000 after buying an additional 84 shares during the last quarter. Finally, Clayton Financial Group LLC raised its stake in Abbott Laboratories by 1.4% during the fourth quarter. Clayton Financial Group LLC now owns 6,217 shares of the healthcare product maker’s stock valued at $779,000 after buying an additional 84 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Up 3.3%

Shares of Abbott Laboratories stock opened at $95.25 on Friday. The stock has a market capitalization of $165.91 billion, a price-to-earnings ratio of 26.68, a PEG ratio of 1.59 and a beta of 0.61. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $137.49. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The business’s 50 day simple moving average is $88.88 and its 200-day simple moving average is $104.41.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. The business had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities research analysts forecast that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be given a dividend of $0.63 per share. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.6%. Abbott Laboratories’s dividend payout ratio is currently 70.59%.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks purchased 10,000 shares of the business’s stock in a transaction dated Monday, April 27th. The shares were bought at an average price of $92.65 per share, with a total value of $926,500.00. Following the completion of the acquisition, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This represents a 0.15% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Philip P. Boudreau acquired 2,200 shares of Abbott Laboratories stock in a transaction dated Thursday, April 23rd. The shares were acquired at an average price of $91.50 per share, with a total value of $201,300.00. Following the completion of the transaction, the chief financial officer owned 2,200 shares of the company’s stock, valued at approximately $201,300. This trade represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. 0.46% of the stock is owned by company insiders.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Robert W. Baird initiated coverage on Abbott with an “outperform” rating and a $121 price target, signaling meaningful upside from current levels. Article Title
• Positive Sentiment: Baird’s bullish view follows a broader positive analyst backdrop, with another report highlighting Abbott among Wednesday’s notable Wall Street research calls. Article Title
• Positive Sentiment: Abbott also benefited from news that Tandem Diabetes Care launched compatibility for its t:slim X2 insulin pump with Abbott’s FreeStyle Libre 3 Plus sensor in five international markets, which may support adoption of Abbott’s diabetes device ecosystem. Article Title
• Positive Sentiment: Abbott cleared a major legal risk after the DOJ ended its criminal formula probe, removing a potential overhang that had weighed on the stock. Article Title
• Neutral Sentiment: Some recent coverage compares Abbott with Intuitive Surgical as a healthcare investment idea, but this is more commentary than a direct catalyst for the shares. Article Title

Analyst Upgrades and Downgrades

A number of research firms have commented on ABT. Oppenheimer reduced their target price on Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Evercore dropped their price target on Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Barclays reduced their price objective on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a research note on Monday, April 20th. Piper Sandler reiterated an “overweight” rating and set a $115.00 target price on shares of Abbott Laboratories in a research note on Monday, June 22nd. Finally, Mizuho dropped their target price on shares of Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating on the stock in a report on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average target price of $118.42.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.